ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 70 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $710,549 | -24.2% | 2,179,600 | 0.0% | 0.00% | – |
Q1 2023 | $937,228 | -18.9% | 2,179,600 | 0.0% | 0.00% | – |
Q4 2022 | $1,155,188 | -27.6% | 2,179,600 | +0.0% | 0.00% | – |
Q3 2022 | $1,595,000 | -28.1% | 2,178,590 | +11.9% | 0.00% | – |
Q2 2022 | $2,219,000 | -44.4% | 1,946,590 | 0.0% | 0.00% | – |
Q1 2022 | $3,990,000 | -24.0% | 1,946,590 | +6.8% | 0.00% | – |
Q4 2021 | $5,250,000 | -33.3% | 1,822,859 | -1.9% | 0.00% | – |
Q3 2021 | $7,875,000 | -20.6% | 1,857,250 | -1.0% | 0.00% | – |
Q2 2021 | $9,924,000 | +93.6% | 1,875,871 | +70.1% | 0.00% | – |
Q1 2021 | $5,127,000 | +50.1% | 1,102,528 | +6.5% | 0.00% | – |
Q4 2020 | $3,416,000 | +12.6% | 1,035,402 | +13.0% | 0.00% | – |
Q3 2020 | $3,033,000 | -4.7% | 916,569 | -2.9% | 0.00% | – |
Q2 2020 | $3,182,000 | -48.4% | 944,124 | -41.3% | 0.00% | – |
Q1 2020 | $6,163,000 | -39.0% | 1,609,217 | -3.9% | 0.00% | – |
Q4 2019 | $10,110,000 | -5.0% | 1,673,962 | +18.9% | 0.00% | – |
Q3 2019 | $10,639,000 | -36.3% | 1,407,359 | +14.2% | 0.00% | -100.0% |
Q2 2019 | $16,700,000 | +469.6% | 1,232,456 | +127.8% | 0.00% | – |
Q1 2019 | $2,932,000 | +270.2% | 541,114 | +103.0% | 0.00% | – |
Q4 2018 | $792,000 | -85.1% | 266,617 | -59.1% | 0.00% | – |
Q3 2018 | $5,316,000 | +3.7% | 651,400 | +23.8% | 0.00% | – |
Q2 2018 | $5,124,000 | +3.0% | 526,073 | -8.1% | 0.00% | – |
Q1 2018 | $4,977,000 | -33.6% | 572,694 | -4.4% | 0.00% | – |
Q4 2017 | $7,501,000 | +80.6% | 599,151 | +20.6% | 0.00% | – |
Q3 2017 | $4,154,000 | -48.9% | 496,805 | +3.8% | 0.00% | – |
Q2 2017 | $8,125,000 | -5.1% | 478,763 | +12.4% | 0.00% | – |
Q1 2017 | $8,559,000 | +98.4% | 425,811 | +53.9% | 0.00% | – |
Q4 2016 | $4,314,000 | +51.7% | 276,717 | +27.1% | 0.00% | – |
Q3 2016 | $2,843,000 | +103.2% | 217,793 | +6.6% | 0.00% | – |
Q2 2016 | $1,399,000 | -28.2% | 204,215 | -0.9% | 0.00% | – |
Q1 2016 | $1,948,000 | +182.3% | 206,111 | +200.8% | 0.00% | – |
Q4 2015 | $690,000 | +43.5% | 68,521 | +103.6% | 0.00% | – |
Q3 2015 | $481,000 | – | 33,648 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 507,191 | $5,107,000 | 0.50% |
Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |